Risk of macrovascular complications in statin-treated patients developing diabetes

To assess the risk of macrovascular complications in patients developing diabetes from statin treatment. In this population-based cohort study, 40,409 participants who began to receive statin therapy between 2000 and 2012 were enrolled in to the study group, and another 1:1 matched adults without st...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2019-11, Vol.157, p.107870-107870, Article 107870
Main Authors: Chen, Yin-Huei, Yang, Yu-Cih, Chen, Weishan, Lin, Yen-Nien, Hung, Yi-Chih
Format: Article
Language:English
Subjects:
Aged
Cohort Studies
Cohort study
Diabetes mellitus
Diabetes Mellitus - drug therapy
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hyperlipidemia
Incidence
Macrovascular complications
Male
Microvessels - pathology
Middle Aged
Risk
Statin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the risk of macrovascular complications in patients developing diabetes from statin treatment. In this population-based cohort study, 40,409 participants who began to receive statin therapy between 2000 and 2012 were enrolled in to the study group, and another 1:1 matched adults without statin treatment during the same period served as the control group. Both groups were followed up to identify individuals who later developed diabetes. After a follow-up identification of diabetes, diabetes and non-diabetes cohorts were subjected to an analysis for the risk of macrovascular events between diagnosis of diabetes and December 31, 2013. Compared with individuals without statin therapy, statin-treated patients had a higher risk of developing diabetes (adjusted hazard ratio: 2.46; 95% confidence interval: 2.37–2.57). Compared with statin-treated patients without diabetes, statin-treated participants developing diabetes had a higher overall incidence of macrovascular complications (adjusted hazard ratio: 1.74; 95% confidence interval: 1.62–1.88). Moreover, compared with that of other diabetogenic statins, patients taking pravastatin had a lower risk of developing diabetes (adjusted hazard ratio: 0.63; 95% confidence interval: 0.55–0.73) and macrovascular events (adjusted hazard ratio: 0.64; 95% confidence interval: 0.42–0.98). According to these findings, prescribing statins that have a neutral effect on glucose homeostasis may be advisable for Asian populations.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2019.107870